Ginza Solaria Clinic, Panagy Co., Ltd., Tokyo, Japan.
Department of Urology, Edogawa Hospital, Tokyo, Japan.
J Cell Mol Med. 2022 Jan;26(1):195-201. doi: 10.1111/jcmm.17072. Epub 2021 Nov 29.
Majority of current treatment strategies against erectile dysfunction (ED) has been consisted of only a supportive care to sustain enough erection during a sexual intercourse. In this study, we investigated whether the cultured conditioned medium of human exfoliated deciduous dental pulp stem cells (SHED-CM) had an ability to treat ED through fundamentally repairing the pathological damage of vascular endothelial cells of the corpus cavernosum. An open-label pilot study was performed from April 2016 to October 2020. SHED-CM was injected directly into the corpus cavernosum of penis of 38 ED patients who visited our clinic and fulfilled the inclusion criteria. Efficacy was assessed using the simplified International Index of Erectile Function (IIEF-5) questionnaire. The average age and initial IIEF-5 score of the patients enrolled in this study was 56 (31-79) years old and 13.1 (5-20) points, respectively. Medical history revealed 7 patients with diabetes, 7 patients with hypertension and 1 patient with priapism undergone shunt operation. Of these, 37 patients (97.4%) showed an improvement in IIEF-5 of an average of 19.3 (7-25) points or 64.4 (10-300) % increase after three injections of SHED-CM. Eighteen patients (47.4%) achieved more than 21 points (no ED) in IIEF-5. No adverse events were encountered. This is the first clinical report of ED treatment in the literatures evaluating the efficacy of SHED-CM. Treatment with SHED-CM is expected to repair vascular damages of the corpus cavernosum, which are the main cause of ED, and to be widely spread as a fundamental clinical application for ED.
目前针对勃起功能障碍 (ED) 的大多数治疗策略仅包括支持性护理,以在性交期间维持足够的勃起。在这项研究中,我们研究了人脱落乳牙牙髓干细胞(SHED-CM)的培养条件培养基是否具有通过从根本上修复海绵体血管内皮细胞的病理损伤来治疗 ED 的能力。一项开放标签的初步研究于 2016 年 4 月至 2020 年 10 月进行。SHED-CM 直接注射到来我们诊所并符合纳入标准的 38 名 ED 患者的阴茎海绵体内。使用简化的国际勃起功能指数(IIEF-5)问卷评估疗效。这项研究纳入的患者的平均年龄和初始 IIEF-5 评分为 56(31-79)岁和 13.1(5-20)分。病史显示 7 名糖尿病患者、7 名高血压患者和 1 名接受分流手术的阴茎异常勃起患者。其中,37 名患者(97.4%)的 IIEF-5 改善平均为 19.3(7-25)分,或 64.4%(10-300%)增加,接受三次 SHED-CM 注射后。18 名患者(47.4%)在 IIEF-5 中获得超过 21 分(无 ED)。未发生不良反应。这是文献中首次报道评估 SHED-CM 疗效的 ED 治疗的临床报告。SHED-CM 的治疗有望修复 ED 的主要原因——海绵体的血管损伤,并作为 ED 的一种基础临床应用得到广泛推广。